Literature DB >> 3090961

[Treatment of acute pulmonary embolism with urokinase compared with the combination plasminogen-urokinase. Apropos of 67 cases].

G François, B Charbonnier, P Raynaud, L F Garnier, P Griguer, M Brochier.   

Abstract

Sixty-seven patients with recent acute pulmonary embolism (within 5 days) and an angiographic deficit of over 30% were included in a randomised study designed to compare the efficacy of the associations of urokinase-heparin (Group I) and lysyl-plasminogen-urokinase-heparin (Group II). Plasminogen was administered as an intravenous bolus of 150 microkatal units at the beginning of the urokinase infusion, the dosage of which was set at 2 700 000 IU over 24 hours. Both groups received anticoagulant doses of heparin. The efficacy of treatment was judged by early revascularisation on pulmonary angiography performed during the 24 hours after the end of treatment and by changes in the parameters of fibrinolysis and its inhibitors. The clinical features of the two groups were comparable but the angiographic changes were more pronounced in Group I (deficit: 68.5 +/- 10.4% vs 62.3 +/- 10.9%, p less than 0.02). Treatment had to be stopped before the 24th hour in 4 cases (3 early deaths and 1 severe haemorrhage). The average revascularisation was 30.5 +/- 6.8% in Group I and 38.3 +/- 31.1% in Group II (NS). The alpha-2-antiplasmins were lower (NS) in Group II as were the fibrinogen levels (p less than 0.01 at the 12th and 24th hour) whilst the plasminogen levels and surface of fibrin plateaux were higher (p less than 0.01 at the 6th hour and p less than 0.05 at the 12th hour, respectively). These results show that moderate doses of urokinase associated with heparin are effective in the treatment of acute pulmonary embolism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3090961

Source DB:  PubMed          Journal:  Arch Mal Coeur Vaiss        ISSN: 0003-9683


  6 in total

Review 1.  Comparative tolerability profiles of thrombolytic agents. A review.

Authors:  K S Woo; H D White
Journal:  Drug Saf       Date:  1993-01       Impact factor: 5.606

2.  Indications for thrombolytic therapy in acute pulmonary embolism.

Authors:  J A Dieck; J J Ferguson
Journal:  Tex Heart Inst J       Date:  1989

Review 3.  Use of thrombolytic drugs in non-coronary disorders.

Authors:  M Verstraete
Journal:  Drugs       Date:  1989-11       Impact factor: 9.546

4.  Thrombolytic therapy for pulmonary embolism.

Authors:  Zhiliang Zuo; Jirong Yue; Bi Rong Dong; Taixiang Wu; Guan J Liu; Qiukui Hao
Journal:  Cochrane Database Syst Rev       Date:  2021-04-15

5.  Thrombolytic therapy for pulmonary embolism.

Authors:  Qiukui Hao; Bi Rong Dong; Jirong Yue; Taixiang Wu; Guan J Liu
Journal:  Cochrane Database Syst Rev       Date:  2018-12-18

6.  Systematic review and meta-analysis for thrombolysis treatment in patients with acute submassive pulmonary embolism.

Authors:  Yaoqian Cao; Haiyan Zhao; Wanpeng Gao; Yan Wang; Jie Cao
Journal:  Patient Prefer Adherence       Date:  2014-02-28       Impact factor: 2.711

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.